Journal: RSC Chemical Biology
Article Title: Development of isourea-based covalent GPX4 inhibitors and structure–activity relationship analysis in ferroptosis induction
doi: 10.1039/d6cb00321d
Figure Lengend Snippet: Compound 100 induces ferroptosis and engages GPX4 in cancer cells. (A) Relative viability of human cancer cell lines (ES-2, 786-O, 769-P, OVCAR-8, Daudi, and SU-DHL-4) and mouse cancer cell lines (LLC1 and MC-38) treated with KY0100, ML210, or RSL3 in the presence or absence of Lip-1. (B) Representative BODIPY-C11 fluorescence images of ES-2 cells treated with DMSO or increasing concentrations of compound 100 (0.5–5 µM), with or without Lip-1. Reduced and oxidized BODIPY-C11 signals are shown separately and as merged images. Scale bars, 50 µm. (C) Chemical structures of compound 100-yne and the control alkyne and schematic workflow for cellular labeling, CuAAC conjugation, affinity enrichment, in-gel fluorescence, and immunoblot analysis. (D) Relative viability of LLC1 cells treated with KY0100 or KY0100-yne in the presence or absence of Lip-1. (E) In-gel fluorescence of LLC1 cells treated with DMSO, control alkyne, or compound 100-yne. (F) GPX4 immunoblot analysis of input, unbound, and affinity-enriched fractions following compound 100-yne labeling of LLC1 cells.
Article Snippet: Human 786-O clear-cell renal cell carcinoma cells (ATCC, CRL-1932), ES-2 ovarian clear-cell carcinoma cells (ATCC, CRL-1978), 769-P renal carcinoma cells (ATCC, CRL-1933), and MDA-MB-468 breast carcinoma cells (ATCC, HTB-132) were obtained from the American Type Culture Collection (ATCC).
Techniques: Fluorescence, Control, Labeling, Conjugation Assay, Western Blot, Analysis